Molecular Imaging and Biology

, 11:473

Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma

  • S. T. Lee
  • M. Ghanem
  • R. A. Herbertson
  • S. U. Berlangieri
  • A. J. Byrne
  • K. Tabone
  • P. Mitchell
  • S. R. Knight
  • M. Feigen
  • A. M. Scott
Research Article

DOI: 10.1007/s11307-009-0203-6

Cite this article as:
Lee, S.T., Ghanem, M., Herbertson, R.A. et al. Mol Imaging Biol (2009) 11: 473. doi:10.1007/s11307-009-0203-6

Abstract

Purpose

To evaluate prognostic value of integrated 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) and correlate histopathological subtype with maximum standardized uptake value (SUVmax) and survival in patients with malignant mesothelioma (MM).

Procedures

Retrospective review of FDG-PET/CT scans, with derivation of SUVmax of FDG-avid lesions, was performed in patients with biopsy-proven MM. Clinical follow-up and Kaplan–Meier survival analysis was performed.

Results

Forty-six patients (37 M:9 F; mean age 61 years) with MM had a FDG-PET/CT scan in a 30-month period. Follow-up was available on 44/46 (96%) patients. Metastatic disease was detected in 9/46 (20%) patients on FDG-PET/CT, where 8/9 were previously undetected. Better survival was found in patients without metastases (p value < 0.05). Mean SUVmax of primary pleural lesions in patients with metastatic disease was significantly higher than in patients without metastatic disease (p value < 0.05). Progression-free survival was significantly better in the epithelioid histology group compared to the biphasic group (p value 0.015).

Conclusions

Detection of extrathoracic metastases on FDG-PET/CT and nonepithelioid histopathology are poor prognostic indicators in patients with MM.

Key words

FDG-PET/CTMesotheliomaPrognosisPET

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • S. T. Lee
    • 1
    • 2
    • 3
  • M. Ghanem
    • 1
  • R. A. Herbertson
    • 3
    • 4
  • S. U. Berlangieri
    • 1
  • A. J. Byrne
    • 1
  • K. Tabone
    • 1
  • P. Mitchell
    • 2
    • 4
  • S. R. Knight
    • 5
  • M. Feigen
    • 6
  • A. M. Scott
    • 1
    • 2
    • 3
  1. 1.Centre for PETAustin HealthHeidelbergAustralia
  2. 2.Department of MedicineUniversity of Melbourne, Austin HealthHeidelbergAustralia
  3. 3.Ludwig Institute for Cancer Research, Melbourne Centre for Clinical SciencesAustin HealthHeidelbergAustralia
  4. 4.Ludwig Institute Oncology UnitAustin HealthHeidelbergAustralia
  5. 5.Department of Thoracic SurgeryAustin HealthHeidelbergAustralia
  6. 6.Department of Radiation OncologyAustin HealthHeidelbergAustralia